[go: up one dir, main page]

MX2016012127A - Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos. - Google Patents

Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos.

Info

Publication number
MX2016012127A
MX2016012127A MX2016012127A MX2016012127A MX2016012127A MX 2016012127 A MX2016012127 A MX 2016012127A MX 2016012127 A MX2016012127 A MX 2016012127A MX 2016012127 A MX2016012127 A MX 2016012127A MX 2016012127 A MX2016012127 A MX 2016012127A
Authority
MX
Mexico
Prior art keywords
ostreolysin
extract
functionally related
related variant
variant
Prior art date
Application number
MX2016012127A
Other languages
English (en)
Inventor
Schwartz Betty
Yehuda-Shnaidman Einav
NIMRI Lili
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of MX2016012127A publication Critical patent/MX2016012127A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describen métodos para tratar, prevenir y aliviar obesidad, síndrome de hígado graso, diabetes, una o más afecciones o complicaciones del síndrome metabólico y/o cáncer, que comprende administrar una cantidad efectiva de ostreolisina, su variante funcionalmente relacionada, o un extracto o extracto de hongo que comprende la misma, a sujetos que necesitan de la misma.
MX2016012127A 2014-03-19 2015-03-18 Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos. MX2016012127A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461955338P 2014-03-19 2014-03-19
US201461955874P 2014-03-20 2014-03-20
US201462082308P 2014-11-20 2014-11-20
PCT/IL2015/050283 WO2015140798A2 (en) 2014-03-19 2015-03-18 Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof

Publications (1)

Publication Number Publication Date
MX2016012127A true MX2016012127A (es) 2017-04-13

Family

ID=53488382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012127A MX2016012127A (es) 2014-03-19 2015-03-18 Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos.

Country Status (10)

Country Link
US (3) US10493123B2 (es)
EP (2) EP3119414B1 (es)
JP (2) JP2017510635A (es)
CN (1) CN106232134B (es)
AU (2) AU2015232974A1 (es)
CA (2) CA3075791C (es)
ES (1) ES2746258T3 (es)
IL (2) IL247838B (es)
MX (1) MX2016012127A (es)
WO (1) WO2015140798A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232134B (zh) 2014-03-19 2019-12-20 耶路撒冷希伯来大学伊森姆研究发展有限公司 珍菇毒蛋白、其功能上相关的变体、包含珍菇毒蛋白的抽提物及其用途
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
KR102429280B1 (ko) * 2020-06-29 2022-08-05 (주)노바셀테크놀로지 신규 교잡품종 버섯의 분말을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 또는 건강기능성식품

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2911097B2 (ja) * 1994-02-25 1999-06-23 カゴメ株式会社 糖タンパク質及びこれを有効成分とする食欲抑制剤
FR2805465B1 (fr) * 2000-02-28 2003-02-21 Medecine Information Formation Nouvelles compositions pharmaceutique ou dietetiques a base de champignons
CA2414912A1 (en) * 2001-12-20 2003-06-20 University Of Saskatchewan Technologies Inc. Pleurotus extract and use in treating hypertension
KR20040057973A (ko) * 2002-12-26 2004-07-02 요시노부 기타지마 플레우로투스 네브로덴시스의 재배방법 및 플레우로투스네브로덴시스를 포함하는 질환 예방 개선제
WO2004096252A1 (en) * 2003-04-25 2004-11-11 Primavera Biosciences, Inc. Compositions and methods for weight loss
JP2006195645A (ja) * 2005-01-12 2006-07-27 Fuji Photo Film Co Ltd データ送受信装置
TWI519307B (zh) * 2007-10-24 2016-02-01 Suntory Holdings Ltd The ligand of peroxisome proliferator activated receptor (PPAR)
KR20120132207A (ko) * 2011-05-27 2012-12-05 (주) 해뜰날 버섯균사체쌀 추출물을 포함하는 당뇨병 또는 비만 치료용 약학 조성물
CN106232134B (zh) * 2014-03-19 2019-12-20 耶路撒冷希伯来大学伊森姆研究发展有限公司 珍菇毒蛋白、其功能上相关的变体、包含珍菇毒蛋白的抽提物及其用途

Also Published As

Publication number Publication date
EP3119414A2 (en) 2017-01-25
CA3075791A1 (en) 2015-09-24
JP2020040966A (ja) 2020-03-19
EP3257520B1 (en) 2020-01-29
IL267555B (en) 2020-04-30
US20170368133A1 (en) 2017-12-28
CA2943306A1 (en) 2015-09-24
AU2020201858A1 (en) 2020-04-02
CN106232134B (zh) 2019-12-20
JP6774138B2 (ja) 2020-10-21
AU2015232974A1 (en) 2016-10-06
US10716825B2 (en) 2020-07-21
CN106232134A (zh) 2016-12-14
JP2017510635A (ja) 2017-04-13
WO2015140798A3 (en) 2016-02-25
US10493123B2 (en) 2019-12-03
HK1246651A1 (en) 2018-09-14
IL247838B (en) 2019-06-30
ES2746258T3 (es) 2020-03-05
CA3075791C (en) 2021-03-30
WO2015140798A2 (en) 2015-09-24
EP3257520A2 (en) 2017-12-20
IL247838A0 (en) 2016-11-30
US20200397848A1 (en) 2020-12-24
EP3119414B1 (en) 2019-08-07
US20200085905A1 (en) 2020-03-19
AU2020201858B2 (en) 2020-05-07
EP3257520A3 (en) 2018-02-28
IL267555A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2017009532A (es) Uso de acidos grasos de cadena corta en prevencion de cancer.
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
ECSP16075472A (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
HK1243929A1 (zh) Tlr抑制剂和布鲁顿酪氨酸激酶抑制剂组合
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
IL259183B (en) Food supplement and preparation for the treatment of metabolic syndrome
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
WO2015009591A3 (en) Treatment for melanoma
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2015008310A (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2016012127A (es) Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos.
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
PH12016501838A1 (en) Compounds and their methods of use
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2020005454A (es) Tratamiento de cancer mejorado.
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.

Legal Events

Date Code Title Description
FG Grant or registration